Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -16.93% and Operating profit at -52.02% over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
3
With ROE of 2.22%, it has a very attractive valuation with a 1.54 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,284 Million (Mid Cap)
70.00
NA
6.82%
-0.62
2.46%
0.81
Revenue and Profits:
Net Sales:
187 Million
(Quarterly Results - Sep 2025)
Net Profit:
42 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.82%
0%
3.82%
6 Months
-4.98%
0%
-4.98%
1 Year
8.23%
0%
8.23%
2 Years
-5.45%
0%
-5.45%
3 Years
-32.85%
0%
-32.85%
4 Years
-60.9%
0%
-60.9%
5 Years
0%
0%
0.0%
Sino Biological Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-16.93%
EBIT Growth (5y)
-52.02%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.68
Sales to Capital Employed (avg)
0.11
Tax Ratio
9.18%
Dividend Payout Ratio
104.93%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
129.55%
ROE (avg)
16.65%
Valuation key factors
Factor
Value
P/E Ratio
70
Industry P/E
Price to Book Value
1.54
EV to EBIT
147.43
EV to EBITDA
37.40
EV to Capital Employed
2.53
EV to Sales
8.31
PEG Ratio
NA
Dividend Yield
3.31%
ROCE (Latest)
1.72%
ROE (Latest)
2.22%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
187.00
159.30
17.39%
Operating Profit (PBDIT) excl Other Income
34.30
35.90
-4.46%
Interest
0.80
1.10
-27.27%
Exceptional Items
10.60
-2.20
581.82%
Consolidate Net Profit
42.50
28.40
49.65%
Operating Profit Margin (Excl OI)
183.50%
62.80%
12.07%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 17.39% vs -13.28% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 49.65% vs -59.14% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
613.70
646.30
-5.04%
Operating Profit (PBDIT) excl Other Income
129.80
213.20
-39.12%
Interest
4.60
4.10
12.20%
Exceptional Items
4.90
11.00
-55.45%
Consolidate Net Profit
121.90
260.10
-53.13%
Operating Profit Margin (Excl OI)
47.40%
209.30%
-16.19%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -5.04% vs 13.81% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -53.13% vs -14.16% in Dec 2023
About Sino Biological Inc. 
Sino Biological Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






